Clinical trial Recruiting at 1 site Interventional Ages 5 to 14

Teleo virtual therapy for kids: testing engagement and outcomes in clinical care

Official title: Phase II: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settings

Run by Stanford University · NCT07155707 · Data updated 2026-11-12

We’re testing whether Teleo, a kid-focused virtual therapy platform, keeps young patients more engaged and improves anxiety and mood symptoms compared with standard video calls.

More Anxiety trials

Quick facts

Study typeInterventional
Ages5 Years to 14 Years
SexAll
Enrollment156 (estimated)
SponsorStanford University
Academic / other
Locations2 sites (Monterey, California and 1 other locations)
StatusRecruiting
StartedJune 24, 2026
Main results expectedSeptember 15, 2027
Study endsSeptember 15, 2027
Registry record updatedJune 29, 2026
Trial IDNCT07155707 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are English-speaking youths with mood or anxiety disorders starting psychotherapy at one of the study sites and meeting RCADS thresholds who can participate via telehealth.

Probably not a fit

Individuals with contraindications to telehealth or who do not respond to teletherapy may not experience additional benefit over standard care.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase II trial will compare engagement and clinical outcomes between Teleo, a tailored telehealth psychotherapy environment for youth, and standard videoconferencing. The study plans to enroll 156 families across two sites to see how each approach affects treatment attendance, clinician satisfaction, treatment duration, medication needs, and symptoms of anxiety and depression. Participants are children and adolescents with mood or anxiety disorders who can participate in English and are starting therapy at one of the study sites. Exclusion criteria include intellectual disability, autism spectrum disorder, psychotic disorders, high-risk suicidality, substance use disorders, or conditions hindering telehealth engagement. The lead sponsor is Stanford University, with collaboration from NIMH and MainSquare Co. (Teleo).

Why it matters

Potential benefit: If Teleo improves engagement and clinical outcomes, participants may experience better symptom relief and smoother access to care.

How similar studies have gone: Previous studies in pediatric telepsychiatry suggest that tailored digital therapy environments can improve engagement and certain outcomes, but results vary by platform and population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosed with a mood and/or anxiety disorder
* Have proficiency to participate in psychotherapy in English
* Scheduled to begin therapy at one of the study sites
* RCADS score \> 65

Exclusion Criteria:

\- Comorbid diagnosis of intellectual disability, autism spectrum disorder, psychotic disorders, high-risk suicidal behaviors requiring immediate hospitalization, substance use disorders, or other physical or mental condition that would prohibit them from engaging in telehealth settings.

Where it's running

  • Stanford University
    Stanford, California, United States
    Recruiting
  • Ohana Center for Child and Adolescent Behavioral Health
    Monterey, California, United States
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.